3D High Resolution Magnetic Resonance Fingerprinting for Prostate Cancer

项目摘要 目标是使用快速的， 定量磁共振成像（MRI）方法。患者的标准治疗 对怀疑前列腺癌的评估是对整个腺体进行系统采样， 12个活检芯，在成像上没有识别出疑似癌症的病灶。当前质量 磁共振图像，而大多数成功地突出前列腺癌，可能看起来不同， 扫描仪到扫描仪，甚至在同一台扫描仪上重复。这种可变性增加了复杂性 到一个已经主观的诊断癌症的解释过程， 临床上显著且无痛的疾病。因此，更强大和标准化的MRI方法， 需要检测和表征临床上显著的前列腺癌。 该项目计划解决这一问题，具体目标如下： (1)将开发并优化用于前列腺的快速高分辨率3D MRF采集 通过创新缩小视野成像、3D笛卡尔采样和 在MRF中进行高级重建。建议的MRF采集将实现准确的T1和T2 在前列腺上以各向同性亚毫米分辨率（0.8 mm3）进行映射， 采集时间小于5分钟。 (2)使用基于MRF的T1和T2标测图合成的对比度加权图像将取代 常规定性图像用于检测前列腺癌。 (3)将验证基于MRF的T1和T2（具有表观扩散系数），以区分癌症 与非癌症区分开来，并区分不同级别的癌症。 (4)来自MRF的前列腺癌的显微结构特征将提供以下信息： 亚体素成分（上皮、间质、管腔及其体积分数），以揭示隐匿性 癌症，并能够区分不同级别的癌症。 该项目将通过提供可再现和可重复的非侵入性技术来推进前列腺成像。 定量成像指标。这些创新将取代传统的对比度加权 使用单一快速高分辨率标准MRF协议进行成像， 前列腺癌的鉴别和分级，完善前列腺癌的分类 使用显微结构特征，从而减少不必要的活检， 治疗选择

Project Summary Abstract The goal is to identify and characterize prostate cancer objectively and accurately using a rapid quantitative Magnetic Resonance Imaging (MRI) approach. The standard-of-care in patients being evaluated for suspicion of prostate cancer is systematic sampling of the entire gland with 12 biopsy cores, without an identified focus suspicious for cancer on imaging. Current qualitative MR images, while mostly successful in highlighting prostate cancer, may look different from scanner to scanner, or even when repeated on the same scanner. This variability adds complexity to an already subjective interpretive process of detecting cancer and discriminating between clinically significant and indolent disease. Thus, more robust and standardized MRI methods to detect and characterize clinically significant prostate cancer are needed. This project plans to address this issue with following specific aims: (1) A rapid high-resolution 3D MRF acquisition will be developed and optimized for prostate cancer assessment by innovating reduced field-of-view imaging, 3D Cartesian sampling, and advanced reconstruction in MRF. The proposal MRF acquisition will enable accurate T1 and T2 mapping over the prostate gland with an isotropic submillimeter resolution (0.8 mm3) in an acquisition time of less than 5 minutes. (2) Contrast-weighted images synthesized using MRF-based T1 and T2 maps will replace conventional qualitative images for detecting prostate cancer. (3) MRF-based T1 and T2 with apparent diffusion coefficient will be validated to separate cancer from non-cancer and differentiate cancers with different grades. (4) Microstructural signatures of prostate cancer derived from MRF will provide information about subvoxel components (epithelium, stroma, lumen, and their volume fractions) to reveal occult cancers and enable the discrimination of different grades of cancer. This project will advance prostate imaging by providing reproducible and repeatable non-invasive quantitative imaging metrics. These innovations will replace conventional contrast-weighted imaging with a single rapid high-resolution standard MRF protocol, provide an objective identification of prostate cancer and grading, and improve the classification of prostate cancer using microstructural signatures, thus reducing unnecessary biopsies and facilitating appropriate treatment selection.